JS Link

JS Link EBITDA Margin

The EBITDA Margin of JS Link (127120.KQ) as of Oct 29, 2026 is -88.52 %. In the previous year, EBITDA Margin was -20.00 % — a change of 342.64% (lower).

EBITDA Margin

-88.52 %

YoY

342.64%

Last updated:

EBITDA Margin of JS Link is 2024 -88.52 % . EBITDA Margin of JS Link was 2023 -20.00 % . It decreases by 342.64% lower compared to the previous year.

The JS Link EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2017
10.51 KRW
Jan 1, 2018
-25.80 KRW
Jan 1, 2019
-50.26 KRW
Jan 1, 2020
-62.65 KRW
Jan 1, 2021
-22.13 KRW
Jan 1, 2022
-47.62 KRW
Jan 1, 2023
-20.00 KRW
Jan 1, 2024
-88.52 KRW
The JS Link EBITDA Margin history
YEAREBITDA MarginYoY
-88.52 %+342.64%
-20.00 %-58.00%
-47.62 %+115.16%
-22.13 %-64.68%
-62.65 %+24.66%
-50.26 %+94.80%
-25.80 %-345.56%
10.51 %-115.34%
-68.49 %-18.64%
-84.18 %+84.44%
-45.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JS Link Stock analysis

What does JS Link do? DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description. JS Link is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JS Link stock

EBITDA Margin of JS Link is -88.52 % in 2024.

EBITDA Margin of JS Link changed from -20.00 % to -88.52 %, representing a 342.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin JS Link since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's JS Link with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — JS Link

All Key Metrics — JS Link